Small Intestine

A single patient, eighteen months out from her last resection and finally stable enough to think past survival. The disagreement isn’t about whether she needs a GLP-2 analog — it’s about which one, when neither drug’s own trial was built to answer that question for her specific anatomy.

A single patient, five years into a genuine teduglutide response, raising the question himself: does he actually still need this, or has the drug just been quietly propping up a plateau nobody has tested in years?

A single patient, a year into a gluten-free diet that should have worked and hasn’t. The disagreement isn’t just which drug induces remission faster — it’s whether either plan on the table actually accounts for what happens after remission is reached.

Two patients, both refractory to a strict gluten-free diet, both diagnosed by the same flow cytometry panel — but one result comes back clean and the other comes back aberrant, and that single laboratory line changes what kind of disease the team is actually treating.

A single patient, back in clinic for the third time in two years with the same bloating and diarrhea. The disagreement isn’t whether he has SIBO again — it’s whether that question is even still worth formally re-asking, or whether his anatomy has already answered it for good.

A single patient, iron-deficient and asymptomatic, with a small bowel that’s been quietly injured by exactly the drug her stomach was already being protected from. The disagreement is about where the protection actually needs to be aimed.

A single patient, finally diagnosed after two years of migrating joint pain nobody connected to his gut. The disagreement isn’t about starting antibiotics — it’s about which maintenance regimen a genuine, if imperfect, mechanistic argument says the old standard may not actually be killing the organism at all.

A single patient, home three months from an assignment that ended over a year ago, with a chronic diarrhea nobody could source until someone finally asked the right travel question. The disagreement is over how long a fifty-year-old treatment regimen, built on a different population, actually needs to run for her.

A single patient, six months into octreotide therapy for a small bowel neuroendocrine tumor, still running to the bathroom eight times a day. The disagreement is over whether her regimen has actually been maximized yet, or whether it’s the wrong mechanism for what’s still uncontrolled.

A single patient, forty pounds lighter than he was six months ago, with a diagnosis so rare that no drug proposed for him tonight has ever been tested against another in a real trial. The disagreement is about which thin evidence to trust first.

A single patient, twenty-nine and facing a lifetime disease with no drug that reliably works against it. The disagreement isn’t whether a prokinetic might help — it’s whether "might" is worth the trial when nobody has confirmed there’s any functioning muscle left for it to act on.

A single patient, years past the pelvic radiation that cured his cancer, now living with a chronic diarrhea whose exact cause the standard confirmatory test in the U.S. essentially cannot answer. The disagreement is about how much confirmation an empiric trial actually needs.

A single patient, five days into high-dose steroids with no real improvement, whose melanoma is responding to the exact drug now attacking her gut. The disagreement is between two biologics that have never been tested against each other in a real trial.

A single patient, two weeks past a mesenteric stent that finally stopped the pain of eating. The disagreement is over how long to protect that stent with a drug regimen built almost entirely from studies of arteries that aren’t his. ---